Date: Sunday, November 8, 2015
Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: CXCL10 is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary lymphoid tissues, and the expression is upregulated by TNF-α, via T cell stimulation. It appears that CXCL10 and CXCL13 could play a potential role in the pathogenesis of adult-onset Still’s disease (AOSD), therefore, we investigated the associations between CXCL10 and CXCL13 levels and clinical manifestations in patients with active AOSD.
Methods: Blood samples were collected from 39 active AOSD patients and 40 healthy controls (HC). Of the AOSD patients, follow-up samples were collected from 15 9.6 ± 9.2 months later. CXCL10, CXCL13, and CXCR3 expression levels in biopsy specimens obtained from 26 AOSD patients with skin rashes were investigated via immunohistochemistry.
Results: The CXCL10 level of AOSD patients (1,031.3 ± 2,019.6 pg/mL) was higher than that of HC (104.4 ± 47.9 pg/mL, p=0.006). Also, the CXCL13 level of AOSD patients (158.8 ± 151.2 pg/mL) was higher than that of HC (23.5 ± 18.1 pg/mL, p<0.001). Serum CXCL10 levels correlated with ferritin and systemic scores. Serum CXCL13 levels correlated with those of hemoglobin, C-reactive protein, ferritin, and albumin, and systemic scores. In follow-up AOSD patients, the levels of CXCL10 and CXCL13 fell significantly (153.7 ± 130.1 pg/mL, p=0.002, and 89.1 ± 117.4 pg/mL, p=0.001, respectively). On immunohistochemistry, the percentages of inflammatory cells expressing CXCL10 ranged from 1 to 85%, CXCL13 from 1 to 72%, and CXCR3 from 2 to 65%. The percentage of CXCL10-positive inflammatory cells was higher in skin biopsy samples exhibiting mucin deposition than in those that did not (p=0.01). CXCL13 levels were correlated with those of CD4 and CD68.
Conclusion: Serum CXCL10 and CXCL13 levels may serve as clinical markers for assessment of disease activity in AOSD. CXCL10/CXCR3 and CXCL13 may contribute to the inflammatory response, especially skin manifestations thereof, in AOSD.
To cite this abstract in AMA style:Kim HA, Kim IJ, Han JH, Suh CH, Jung J. Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/association-of-cxcl10-and-cxcl13-levels-with-disease-activity-and-cutaneous-manifestation-in-active-adult-onset-stills-disease/. Accessed January 27, 2020.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-cxcl10-and-cxcl13-levels-with-disease-activity-and-cutaneous-manifestation-in-active-adult-onset-stills-disease/